Status:

COMPLETED

Novel Smoking Cessation Drug for Schizophrenia

Lead Sponsor:

K.N. Roy Chengappa

Collaborating Sponsors:

University of Pittsburgh

National Institutes of Health (NIH)

Conditions:

Smoking Cessation

Eligibility:

All Genders

18-66 years

Phase:

PHASE2

Brief Summary

The investigators will evaluate effects of a novel drug that improves nicotinergic receptor function vs. placebo on short-term smoking abstinence in smokers with schizophrenia who have a high interest...

Detailed Description

Objective: This is a Proof of Concept study planned over nearly 2 years to determine the potential efficacy of a novel drug for smokers with schizophrenia. This study will assess 60 smokers with a d...

Eligibility Criteria

Inclusion

  • List the specific criteria for inclusion of potential subjects.
  • Men or women of any race, ages 18 to 65 years, (≥18 years, ≤ 66 years)
  • Willing to provide written informed consent
  • MINI (Sheehan et al 1998, 2008) chart and/or clinician consensus affirmed DSM IV TR or (DSM -V) diagnoses of schizophrenia or schizoaffective disorder.
  • Patients whose PANSS total scores have been stable for ≥ 4 weeks (clinician and/or subject affirmed) and at ≤ 70
  • No recent ( ≤ 3months) hospitalization, aggression, or suicidal attempts
  • Stable doses of antipsychotic medication, ≥ 4 weeks
  • Smoking
  • Smoke ≥ 5 cigarettes/day
  • Smoking cigarettes ≥ 1 year

Exclusion

  • Smoking/Nicotine Exclusions:
  • Use of smokeless tobacco or snuff or chewing tobacco
  • Use of e-cigarettes, or any non-tobacco nicotine products (e.g. nicotine gum, lozenges, patch, etc.)
  • Current enrollment or plans to enroll in another smoking cessation program. (Bupropion use for depression will be assessed on a case by case basis)
  • Alcohol/Illicit Substance

Key Trial Info

Start Date :

September 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 9 2017

Estimated Enrollment :

62 Patients enrolled

Trial Details

Trial ID

NCT02230384

Start Date

September 1 2014

End Date

March 9 2017

Last Update

April 2 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Western Psychiatric Institute and Clinic and affilated sites

Pittsburgh, Pennsylvania, United States, 15213

Novel Smoking Cessation Drug for Schizophrenia | DecenTrialz